Related Experiment Videos
[Single agent carboplatin therapy for advanced seminoma]
M Kawakita1, S Fukuzawa, T Terachi
1Department of Urology, Faculty of Medicine, Kyoto University.
Hinyokika Kiyo. Acta Urologica Japonica
|June 1, 1994
Summary
Single agent carboplatin shows promise for advanced seminoma, offering a less toxic treatment option with a 60% complete response rate. Careful management of residual masses is crucial due to potential recurrence.
Area of Science:
- Oncology
- Pharmacology
Context:
- Advanced seminoma presents a therapeutic challenge.
- Previous treatments like VAB6 have significant toxicities.
Purpose:
- To evaluate the efficacy and toxicity of single-agent carboplatin in advanced seminoma patients.
Summary:
- Five patients with advanced seminoma received carboplatin (400 mg/m2) for 3-4 cycles.
- Achieved a 60% overall complete response rate and 100% survival.
- Carboplatin demonstrated significantly lower toxicity (nausea, vomiting) compared to VAB6 (leukopenia, alopecia, thrombocytopenia).
- Residual masses require further treatment (surgery, cisplatin-based chemotherapy, radiotherapy) or close observation due to recurrence risk.
Impact:
- Single-agent carboplatin offers an effective and well-tolerated treatment for advanced seminoma.
- Improved patient quality of life due to reduced side effects.
- Highlights the need for specific management strategies for residual masses post-carboplatin therapy.